Tesamorelin

Tesamorelin is a stabilized synthetic peptide analog of growth hormone-releasing hormone (GHRH 1-44) containing a trans-3-hexenoic acid modification at position 2, designed to enhance resistance to enzymatic degradation and prolong biological activity. In laboratory and controlled clinical research, Tesamorelin binds to GHRH receptors on pituitary somatotrophs, activating adenylate cyclase and cAMP-dependent signaling pathways that stimulate endogenous growth hormone (GH) synthesis and pulsatile secretion. Its structural modification differentiates it from native GHRH by improving peptide stability and receptor engagement in endocrine research settings.

In vitro systems and structured clinical investigations evaluate endpoints including GH secretion dynamics, receptor binding kinetics, intracellular cAMP activation, and downstream insulin-like growth factor-1 (IGF-1) response patterns relative to baseline measures. Additional research examines pharmacokinetic profiles, somatotropic axis modulation, peptide stability parameters, and metabolic signaling markers associated with lipid metabolism and body-composition variables under controlled conditions.